THURSDAY, Dec. 12, 2024 (HealthDay News) -- The Advisory Committee on Immunization Practices (ACIP) recommendations have been updated for the meningococcal serogroup B MenB-4C vaccine (Bexsero ...

Sunday 13 Apr 2025. GlaxoSmithKline recently held a high-level scientific conference in conjunction with the launch of “Bexsero,” the first vaccine in Egypt approved by the Egyptian Drug ...

Two new vaccines are cleared to hit the market following the U.S. FDA’s approval over the weekend for Vimkunya, a chikungunya vaccine from Bavarian Nordic A/S, and Penmenvy, a meningococcal vaccine ...

Based on new immunogenicity data, the FDA changed the label for the Bexsero MenB-4C vaccine from a 2-dose schedule at intervals of 0 and at least 1 month to a 2-dose schedule at intervals of 0 and ...

Bexsero is supplied as a suspension for intramuscular injection in 0.5mL single-dose pre-filled syringes. The new dosing schedule will be discussed at a meeting of the Advisory Committee on ...

Bexsero is a vaccine used to help prevent meningitis B.It’s approved by the Food and Drug Administration (FDA) for use in children and adults ages 10 through 25 years.

Bexsero is a brand-name vaccine used to help prevent meningitis B disease. Discover drug interactions in depth, when to avoid Bexsero, and more.

Bexsero (meningococcal group B) is a vaccine used to prevent meningitis B. Bexsero can cause side effects that range from mild to serious. Examples include injection site redness and pain, muscle ...

Bexsero is a vaccine used to prevent meningitis B. Find out what the recommended dosage is, its schedule, how the vaccine is given, and more.